08 dec: Vestas-aktien ramt af Trump-udnævnelse af ny chef for EPA
08 dec: TDC vil købe obligationer tilbage for at reducere gæld - NY
08-12-2016 10:35:35

Zealand increases its share capital as a consequence of exercise of employee warrants

Relateret indhold
15 mar - 
Onsdagens aktier: DSV og Mærsk til tops samt bundrekord..
15 mar - 
Zealand FY: Leverer igen røde tal - men lidt bedre end ..
15 mar - 
Aktier/middag: Banker kravler op i ellers let vigende C..
Relateret debat
25 mar - 
Zealand glider ned under 100, den skal man ihvertfald i..
25 mar - 
Eller salg pga manglende indtægter i Zealand.
24 mar - 
  -0,47 %   106,50     lytter ..

Company announcement - No. 49 / 2016

Zealand increases its share capital as a consequence of exercise of employee warrants

Copenhagen, 8 December 2016 - Zealand Pharma ("Zealand") has increased its share capital with nominal DKK 13,999 divided into 13,999 new shares with a nominal value of DKK 1 each. The increase is a consequence of the exercise of warrants granted under one of Zealand's employee warrant programs. Employee warrant programs are part of Zealand's incentive scheme, and each warrant gives the owner the right to subscribe for one new Zealand share at a pre-specified price, the exercise price, in specific pre-defined time periods before expiration. For further description of Zealand's warrant programs, see the company's Articles of Association, which are available on the homepage: www.zealandpharma.com.

The exercise price is DKK 77 and the total proceeds to Zealand from the capital increase amounts to DKK 1,077,923.

The new shares give rights to dividend and other rights from the time of the warrant holder's exercise notice. Each new share carries one vote at Zealand's general meetings. Zealand only has one class of shares.

The new shares will be listed on Nasdaq Copenhagen after registration of the capital increase with the Danish Business Authority. Following registration of the new shares, the share capital of Zealand will be nominal DKK 26,142,365 divided into 26,142,365 shares with a nominal value of DKK 1 each.

The amendment of Zealand's Articles of Association entailed by the share capital increase has today been registered with the Danish Business Authority.

*****

For further information, please contact:

Mats Blom,

Senior Vice President, Chief Financial Officer

Tel: +45 31 53 79 73, email:mabl@zealandpharma.com

About Zealand Pharma A/S

Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) ("Zealand") is a biotechnology company focused on the discovery, design and development of innovative peptide-based medicines. Zealand has a portfolio of medicines and product candidates under licence collaborations with Sanofi, Boehringer Ingelheim and Helsinn, and a pipeline of proprietary product candidates which primarily target specialty diseases with significant unmet needs.

The company's first invented medicine, lixisenatide, a once-daily prandial GLP-1 analogue for the treatment of type 2 diabetes, is licensed to Sanofi. Lixisenatide is marketed as Lyxumia® outside the United States and approved as Adlyxin(TM) in the United States. Lixisenatide has been developed in a fixed-ratio combination with basal insulin glargine (Lantus®) and is approved as Soliqua(TM) 100/33 in the United States, and in Europe a CHMP positive opinion recommendation was given in November (Suliqua(TM) is the brand name in Europe).  

Zealand's proprietary pipeline includes: Dasiglucagon* (ZP4207) (single-dose rescue treatment) for acute, severe hypoglycaemia (Phase II); Glepaglutide* (ZP1848) for short bowel syndrome (Phase II); Dasiglucagon* (ZP4207) (multiple-dose version) intended for use in a dual-hormone artificial pancreas system for better hypoglycaemia control and diabetes management (in preparation for Phase II); and other earlier stage clinical and preclinical peptide therapeutics.

Zealand is based in Copenhagen (Glostrup), Denmark. For further information about the company's business and activities, please visit www.zealandpharma.com or follow Zealand on Twitter @ZealandPharma.

* Dasiglucagon and Glepaglutide are proposed International Nonproprietary Names (pINN).

49-16_1208 Warrant exercise and capital increase


This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Zealand Pharma via Globenewswire

Vedhæftet fil: 774036.pdf

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
21 mar
ZEAL
Lad os tag en simple P/E betragtning baseret på Alpehus's tal. Lad os se 5 år i krystalkuglen efters..
7
21 mar
ZEAL
Sanofi har både i europa og i USA udtaget patent på lixisenatide tilbrug omid neurodegenrative sygdo..
6
22 mar
ZEAL
Sanofi afrapportere Q1 resultat d. 28 April, 2017. Her vil jeg formode at de giver en eller anden fo..
5
22 mar
ZEAL
Sanofi har satset stort på Soliqua og Zealand Pharma kan næppe finde en mere motiveret samarbejdspar..
4
23 mar
ZEAL
Nu anskuer jeg mine investeringer ud fra den risiko jeg ser fremadrettet, holdt op mod den gevinst j..
3
21 mar
ZEAL
PBM i USA er grådige selskaber som absolut intet tilfører hverken medicin-produkterne eller patiente..
3
23 mar
ZEAL
det var da lige hvad super fjolset gjorde
2
23 mar
ZEAL
Det er nu ikke det Institut for Rationel Farmakoterapi skriver, alpehue!   De skriver, at Saxenda er..
2
22 mar
ZEAL
J-D, du har fuldstændig ret,   Tålmodighed, jeg kan ikke lige huske, eller finde det, men mener der ..
2
21 mar
ZEAL
I takt med direkte kontraktforhandling mellem sundhedssystemet i USA og Big Pharma indføres' vil PBM..
2

Vind/Siemens: Hele vindindustrien vil få glæde af skatterabat

27-03-2017 06:34:14
Som led i et nyt vækstudspil vil Socialdemokratiet indføre en skatterabat på 130 procent for udgifter til forskning og udvikling.Sådan en aftale er efterspurgt blandt flere virksomheder i Danmark. En af dem er Siemens Windpower:- Det vil være en vigtig aftale, som hele vindindustrien vil få glæde af, da det er en industri, der er drevet af innovation og fornyelse.- Og sådan en aftale vil skabe de ..

Novo: EMA-udvalg anbefaler markedsføringstilladelse til Refixia - NY

24-03-2017 13:31:36
Udvalget for humanmedicinske lægemidler (CHMP) ved Det Europæiske Lægemiddelsagentur (EMA) har tildelt Novo Nordisks Refixia en positiv udtalelse og anbefaler en markedsføringstilladelse.Det skriver Novo Nordisk i en fondsbørsmeddelelse.CHMP anbefaler en markedsføringstilladelse til Refixia til unge og voksne med hæmofili B. Til grund for anbefalingen ligger resultater fra udviklingsprogrammet par..

Novo/Exane: Kursmålet skæres til 270 kr.

24-03-2017 10:17:22
Den franske storbank Exane BNP Paribas skærer kursmålet for aktien i Novo Nordisk til 270 kr. fra 295 kr. Anbefalingen er uændret "outperform", viser data fra Bloomberg.Novo-aktien falder fredag 0,4 pct., eller 1 kr., til 233,20 kr. Det dækker dog over en stigning, da aktien ikke længere handles inklusive retten til et udbytte på 4,60 kr./ritzau/FINANSJakob Dalskov +45 33 30 03 35 Ritzau Finans, E..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Aktier/tendens: Trump-forlis kan sende aktier i minus
2
Novo mister tronen som tungeste aktie i C20 Cap
3
Vind/Siemens: Hele vindindustrien vil få glæde af skatterabat
4
G4S/RBC: Løfter kursmålet med 13 pct.
5
Mærsk/Seaintel: Ratesucces 1. april er særligt vigtig

Relaterede aktiekurser

Zealand Pharma A/S 108,50 1,9% Stigning i aktiekurs
Zealand Pharma AS DKK1 15,48 0,0% Aktiekurs uændret

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Euroinvestor A/S 2017  Disclaimer Privatlivspolitik
Aktieinformation leveres af Interactive Data.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
27. marts 2017 10:36:39
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20170324.2 - EUROWEB6 - 2017-03-27 10:36:39 - 2017-03-27 10:36:39 - 1 - Website: OKAY

Når du besøger Euroinvestor.dk accepterer du, at der anvendes cookies, som vi og vores samarbejdspartnere benytter til funktionalitet, statistik og markedsføring. Læs mere om cookies på Euroinvestor.dk her

x